INTRODUCTION
============

The heart undergoes dramatic remodeling under physiological and pathological stress that is associated with changes in gene function ([@gkt896-B1]). Pressure overload by transverse aortic constriction (TAC) upregulates the expression of hypertrophy markers such as *Anp* (*Nppa*) and *Bnp* (*Nppb*), whereas it downregulates *Serca2a* gene expression ([@gkt896-B2]). Cardiac hypertrophy is associated with a shift in myosin heavy chain (MHC) gene expression ([@gkt896-B3]). Chromatin-modifying enzymes and non-coding RNAs (ncRNAs) are thought to mediate gene regulatory functions in cardiac hypertrophy ([@gkt896-B4],[@gkt896-B5]). Chromatin remodeling complexes such as Brg1 and HDAC enzymes are known to regulate genes implicated in hypertrophy by directly associating to the intergenic bi-directional promoter (bdP) of the *α-* and *β-MHC* genes ([@gkt896-B6]). Expression of antisense (AS) RNA (*AS β-MHC*) from the bdP is associated with *β-MHC* gene expression in hypertrophic and hypothyroid animals ([@gkt896-B7],[@gkt896-B8]). Together with the evolutionary conserved *Myh7b* gene, these three myosin genes are regulated by MyomiRs, a family of intronic miRNAs (miR-208a, miR-208b and miR-499) that govern cardiac hypertrophy, growth and muscle performance ([@gkt896-B9],[@gkt896-B10]).

The histone methyltransferase enzyme, Ezh2, regulates gene expression in mature cardiomyocytes ([@gkt896-B11]). Although the functional relevance of the polycomb-group (PcG) histone methyltransferase enzyme, Ezh2, in the healthy heart was recently shown, its role in heart disease remains poorly characterized. Ezh2-deficient mice show increased cardiac growth with upregulated expression of hypertrophic and fibrotic genes such as *Anp*, *Bnp*, *β-MHC* and *Tgfb3* ([@gkt896-B12]). How these genes are precisely regulated by Ezh2 as well as the underlying mechanisms in the hypertrophied heart is not well understood. To study the role of Ezh2, we induced pressure overload by TAC in mice and attenuated the hypertrophy-associated gene expression using histone deacetylase (HDAC) inhibitors. HDAC inhibitors such as trichostatin A (TSA) can reverse pathological hypertrophy and ameliorate cardiac function ([@gkt896-B13]). Structurally diverse HDAC inhibitors can attenuate the induction of hypertrophy markers such as *Anp*, *Bnp* and the embryonic *β-MHC* genes ([@gkt896-B14]).

In this study, we examined the expression of a number of genes implicated in cardiac hypertrophy and assessed chromatin interaction of long ncRNAs in complex with PcG silencing proteins such as Ezh2. Results from TAC animals as well as *in vitro* loss-of-function studies suggest a novel role for Ezh2 and the primary microRNA-208b (pri-miR-208b) transcript. Administration of TSA in TAC mice attenuated the expression of pressure overload-induced hypertrophic and fibrotic genes. These results describe for the first time the interaction of pri-miR-208b targeting specific chromatin modifications and regulation of genes implicated in pathological remodeling of ventricular hypertrophy. These studies provide new insights for specific long non-coding RNAs (lncRNAs) underlying the exchange of regulatory complexes involved with chromatin modification and the control of gene transcription in cardiac hypertrophy.

MATERIALS AND METHODS
=====================

TAC surgery
-----------

Chronic pressure overload was induced by transverse aorta constriction (TAC) performed on C57BL6 male mice at 10--12 weeks of age. TAC mice were injected subcutaneously with either dimethyl sulfoxide (DMSO) or TSA (dissolved in 50% DMSO), twice daily at 0.6 mg/kg/day for a period of 4 weeks. Establishment of hypertrophy and attenuation by TSA was confirmed by echocardiography by measuring left ventricular (LV) wall thickness and dimensions end-diastole and end-systole ([@gkt896-B17]). Sham control animals underwent the same surgical procedures without constriction of the aorta and exhibited no hypertrophy. Non-invasive echocardiographic test was performed at the end of the 4-week study period. Mice were anesthetized with isoflurane (4% for induction and 1.7% for maintenance). Using iE33 ultrasound system (Philips) and a 15-MHz liner-array transducer, 2D short-axis view of the left ventricle (LV) was obtained and M-mode traces were acquired as we previously described ([@gkt896-B18]). LV diameters at diastole and systole (LVDd, LVDs) or wall thickness at diastole was measured, and fractional shortening and LV mass were calculated. Results are presented as mean ±SEM.

Sca1+ cell fractionation and isolation
--------------------------------------

Stem cell antigen-1 positive (Sca-1+) progenitor cells were isolated by magnetic activated cell sorting system using anti-Sca-1 microbeads (Miltenyi Biotech) from differentiated mouse embryonic stem cells by the removal of 103 U/ml leukemia inhibitory factor (ESGRO, Millapore), as previously described ([@gkt896-B19]). In all, 80--95% of isolated cells positive for Sca1 antigen were evaluated by flow cytometry and immunostaining. Sca-1+ and mES cells were cultured on 1% gelatin-coated dishes with Dulbecco's modified Eagle's medium supplemented with ES-qualified fetal bovine serum (FBS), knockout serum replacement, non-essential amino acids, antibiotics (penicillin/streptomycin) and β-mercaptoethanol (Gibco) at 37°C in humid air with 5% CO~2~. To obtain higher numbers of Sca-1+ cells, these cells were allowed to grow in culture without leukemia inhibitory factor for two to eight population doublings.

Mouse neonatal ventricular cardiomyocyte isolation, culture and treatment
-------------------------------------------------------------------------

Day 1---C57BL/6 pups were sacrificed by single cut decapitation procedure and their chests were opened. Hearts were suspended in Hanks solution. Ventricles were carefully dissected and suspended into Hanks + Trypsin solution followed by 4°C incubation overnight on the orbital shaker. Day 2---Tissues were suspended in Hanks + Collagenase medium for tissue dissociation, and resulting cell suspension was collected. This step was repeated until complete tissue dissociation was achieved. The digested extract was pelleted, and adding Dulbecco's modified Eagle\'s medium/10% fetal calf serum (FCS) deactivated the collagenase. The cells were plated in P150 culture dish and incubated for 50 min at 37°C to allow fibroblasts to adhere to the bottom of the dish. Cell suspension was collected and incubated again for 45 min at 37°C to allow the remaining fibroblasts to adhere to the dish. After second incubation, cell suspension was collected into a sterile container. Bromodeoxyuridine (Brdu) (3.15 mg/ml) 100 ul/10 ml media was added, and cells were plated at the density of 0.5 × 10^6^/ml, 2 ml/well (6-well plate). Cardiomyocytes were allowed to settle for 2--3 days followed by serum starvation before TSA treatment was initiated. The serum-starved neonatal ventricular cardiomyocytes were incubated for 48 h in media containing DMSO (vehicle) or TSA (100 nM).

Total RNA preparation
---------------------

For *in vivo* studies, mice heart LV tissue was homogenized in Trizol reagent (Invitrogen) in the presence of RNase inhibitor (SUPERase-In, Ambion). For *in vitro* studies, cultured mouse cardiac progenitor cells were trypsinized and pelleted by centrifugation, and then resuspended with Trizol reagent. Vigorous phenol--chloroform treatment to obtain RNA-containing aqueous phase was followed by purification of RNA using RNeasy Mini Kit preparation columns (Qiagen). DNase treatment ensured removal of residual DNA, and total RNA was accurately quantified using Qubit fluorometer (Invitrogen).

RNA quantification by quantitative reverse transcriptase-polymerase chain reaction
----------------------------------------------------------------------------------

For gene expression studies, total RNA (1--2 µg) was reverse transcribed using high capacity cDNA synthesis kit (Applied Biosystems) in a 20-µl reaction volume containing random primers. For strand-specific quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) of MHC genes, forward and reverse primers were included in separate reactions, and cDNA synthesis was performed at 60°C using Thermoscript cDNA preparation system (Invitrogen) and real-time quantification was performed using Fast SyBr-Green qPCR system (Applied Biosystems). Gene expression levels are expressed as fold difference where relative RNA levels between the control and treatment groups were normalized. The specificity of template amplification was assessed by melt curve analysis. To ensure the RNA strand-specific cDNA synthesis, negative primer controls and negative enzyme controls were included and assessed for negligible non-specific amplification. Oligonucleotide sequences are listed in [Supplementary Data](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1). For miR detection, ∼10 ng of RNA was included in Taqman MicroRNA Reverse transcription kit (PN 4366596). miR-specific RT reactions were carried out for miR-208a (RT000511), miR-208b (RT002290) and control small ncRNA snoRNA135 (RT001230). Relative levels were amplified in PCR using Taqman small RNA Assays for miR-208a (TM000511), miR-208b (TM002290) and snoRNA135 (TM001230). The pri-miR-208b transcript was detected using strand-specific amplification as well as Taqman primary microRNA assays (Applied Biosystems).

Chromatin immunoprecipitation
-----------------------------

For *in vivo* studies, LV tissue was carefully dissected and finely diced. Formaldehyde fixation (1%) was carried out in phosphate buffered saline (w/o Ca^2+^/Mg^2+^) by rotation for 10 min at room temperature, and quenching of excessive formaldehyde was achieved using glycine (0.125 M) ([@gkt896-B17],[@gkt896-B20]). Fixed tissues were washed with ice-cold phosphate buffered saline and homogenized to a clear solution in warm sodium dodecyl sulphate (SDS) lysis buffer containing 1% SDS, 10 mM ethylenediaminetetraacetic acid (EDTA), 50 mM Tris--HCl, pH 8, containing protease inhibitor cocktail (Cayman). Homogenate was placed on ice to ensure proper cell lysis. For *in vitro* studies, cultured cells (∼80% confluent) were formaldehyde (1%) fixed and quenched by adding glycine. Collected cell pellet was lysed in warm SDS lysis buffer. Cell lysates prepared from LV as well as from cultured cells were separated into 300-µl aliquots, and sonication of chromatin was achieved using the bioruptor (Diagnode) with constant power settings. Sheared soluble chromatin was size-fractionated using MultiNA (Shimadzu) to ensure proper sonication of chromatin (∼500 bp). Soluble chromatin (5-µg) was resuspended in chromatin immunoprecipitation (ChIP) dilution buffer containing 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris--HCl, pH 8.0, and 167 mM NaCl. Immunopurification of soluble chromatin was performed using antibodies for specific histone modifications, H3K9/14ac (Millipore 06-599), H3K4m3 (Abcam ab8580), H3K9m3 (Abcam ab8898) and H3K27m3 (Millipore 07-449). Antibodies for histone-modifying enzymes are Ezh2 (Abnova PAB0648), HDAC2 (Sigma H3159) and HDAC1 (Upstate 06-720). The antibody-bound chromatin fraction was precipitated using dynabeads coated with protein A/G (Invitrogen). Conjugates were washed with increasing salt conditions followed by LiCl and SDS washes. Input and antibody-bound isolates were heated at 64°C/2 h in elution buffer containing proteinase K, and the reverse cross-linked DNA was purified by column fractionation (Nucleospin). ChIP-enriched DNA sequences were detected by amplification using real-time qPCR system. Percentage input (% input) was calculated for each ChIP experiment, and results are expressed as relative fold enrichment/ratio for the target sequences compared between the treated versus control groups. The non-specific IgG immunoprecipitation served as control for non-specific background enrichment.

Chromatin RNA immunoprecipitation (RNA-ChIP)
--------------------------------------------

Mice heart LV tissue and cardiac stem cells were formaldehyde fixed, quenched with glycine and resuspended with SDS lysis buffer as described above. To ensure RNA integrity and to protect from RNase degradation, only freshly prepared buffers containing RNase inhibitors were used. Cell lysates were sonicated in the size optimized for RNA (∼1000-bp long), and residual DNA from sheared chromatin was removed by mild DNase treatment. Antibodies that recognize histone H3 (Abcam ab1791) and Ezh2 (Abnova PAB0648) were used in the immunoprecipitation procedure (4°C/4--5 h) to purify RNA associated with chromatin. Conjugates were reverse cross-linked, and RNA was purified using Qiagen RNeasy columns followed by removal of DNA (Roche). Strand-specific reverse transcription of chromatin-associated RNAs and input RNA was performed using Thermoscript reverse transcription protocol (Invitrogen). Relative enrichment of long ncRNAs such as *AS β-MHC* and pri-miR-208b was assessed using qRT-PCR. Strand-specific amplification was ensured using controls as described above.

short-hairpin RNA-mediated knockdown strategy
---------------------------------------------

The knockdown of Ezh2 protein, ncRNAs *AS β-MHC* and pri-miR-208b in Sca1+ vascular progenitors was achieved by MISSION short-hairpin RNA (shRNA) expressing lentivirus vectors (Sigma) as described previously ([@gkt896-B21]). Target sequences are as follows: Ezh2, 5′-GCTAGGCTAATTGGGACC-3′ (TRCN0000039041), shRNA for *AS β RNA* 5′-CTGCTAGTTAGTATCCTACGC-3′ and shRNA for miR-208b 5′-CCGAATATAAGACGAACAAAA-3′. The knockdown of Ezh2 in the cells was verified by qRT-PCR and immunoblots. The knockdown of *AS β-MHC* and pri-miR-208b was verified by strand-specific qRT-PCR assays, as described above. Cells transduced with the MISSION Non-target shRNA control vector (Sigma) served as controls.

Nuclear and cytoplasmic cellular fractionation
----------------------------------------------

Preparation of cytosolic and nuclear fractions was performed as described previously ([@gkt896-B21]). Sca-1+ cells (1 × 10^7^) were resuspended in hypotonic buffer containing 5 mM Tris HCl, pH 7.5, 20 mM KCl, 2 mM MgCl2, 0.25 mM EDTA, 0.125 mM ethylene glycol tetraacetic acid (EGTA), 1 mM Dithiothreitol (DTT), 0.5 mM Phenylmethanesulfonylfluoride (PMSF), 0.05% NP-40 and protease inhibitor (Cayman) for 10 min at 4°C. The cytosolic fraction (supernatant) and the nuclear pellet were separated by centrifugation at 600 *g* for 5 min. The pellet was extracted with buffer containing 20 mM Hepes KOH, pH 7.9, 25% glycerol, 520 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 0.2% NP-40 and protease inhibitor for 15 min at 4 °C. The nuclear fraction was recovered by centrifugation at 15 000 *g* for 15 min. The nuclear and cytosolic fractions were verified by immunoblot procedure using anti-Brm and anti-MeCP2 (nuclear markers) as well as anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (cytoplasmic marker) antibodies.

*In vitro* dsDNA/RNA binding assay
----------------------------------

The intergenic bdP fragment (∼2 kb) corresponding to positions −726 to −2756 relative to *α-MHC* transcription start site was amplified using PCR. One picomole of intergenic bdP fragment was incubated at 37°C for 30 min with 100 pmol of pri-miR-208b (CCUCUCAGGGAAGCUUUUUGCUCGCGUUAUGUUU-BiotinTg) or non-specific (UCCCCUGUGGGUGGGGGUGGGGGGUCUUU-BiotinTg) RNA oligonucleotides (Sigma). The RNA/DNA hybrids were immunoprecipitated using streptavidin-coated beads (Life technologies) in the presence or absence of RNase H or RNase V1. The bdP sequence was amplified using real-time qPCR, and the fold enrichment was determined between the specific and non-specific oligo-enriched samples.

Statistical analysis
--------------------

Data were presented as ±SEM in each group. All data were evaluated with a two-tailed, unpaired Student's *t*-test using QuickCalcs (GraphPad). Statistical significance was obtained by comparing groups viz Sham versus TAC and TAC versus TAC+TSA. For *in vitro* studies, data compared viz non-targets versus shRNA and shRNA versus shRNA+TSA. A value of *P* \< 0.05 was considered statistically significant.

RESULTS
=======

TSA regulates the hypertrophy-induced expression of MHC ncRNAs
--------------------------------------------------------------

The mouse pressure overload model by TAC accelerated LV hypertrophy and heart failure ([Table 1](#gkt896-T1){ref-type="table"}). Administration of TSA following TAC surgery reduced the severity of cardiac hypertrophy ([Figure 1](#gkt896-F1){ref-type="fig"}A). In TAC animals, we examined the expression of hypertrophy-associated genes, and demonstrated that increased *Anp*, *Bnp* and reduced *Serca2a* mRNA expression were attenuated by TSA ([Supplementary Figure S1](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)) ([@gkt896-B13]). We confirmed in TAC animals that induction of hypertrophy altered MHC gene expression (elevated *β-MHC* as well as reduced *α-MHC* gene expression) was attenuated by TSA. Consistent with previous reports ([@gkt896-B7]), expression of *AS β-MHC* from the bdP of the MHC intergenic region was reduced in TAC animals and TSA prevented this reduction. We quantified the expression of miR and report the induction of pri-miR-208b and miR-208b transcripts but not miR-208a in TAC animals were attenuated by TSA administration ([Figure 1](#gkt896-F1){ref-type="fig"}B) ([@gkt896-B22]). The epigenetic regulation of *Anp*, *Bnp* and MHC genes by Ezh2 enzyme in wild-type animals was recently reported ([@gkt896-B11],[@gkt896-B12]). The PcG protein, Ezh2, tri-methylates histone H3 at Lysine 27 (H3K27m3) and mediates gene suppression ([@gkt896-B23]). In TAC animals, we examined the interaction of Ezh2 as well as H3K27m3 modification on *Anp*, *Bnp* and MHC gene promoters by ChIP-qPCR. Ezh2 binding was reduced in hypertrophic animals on the *Anp* and *Bnp* genes and this was not recovered in TSA-administered mice ([Figure 1](#gkt896-F1){ref-type="fig"}C). We also assessed H3K27m3 on *Anp* and *Bnp* promoters by ChIP and observed consistent reduction in TAC mice as well as in TSA-administered animals ([Figure 1](#gkt896-F1){ref-type="fig"}D). These results suggest that the induction of *Anp* and *Bnp* genes in TAC animals is associated with reduced Ezh2 binding and H3K27m3 modification. Figure 1.TAC-induced hypertrophy is associated with the release of Ezh2 at *ANP* and *BNP* genes. (**A**) Pressure overload-induced cardiac hypertrophy in mice was attenuated by TSA administration. Image of Sham (control) and TAC hearts as well as reduced left arterial thrombus following TSA administration (black bar = 5 mm). (**B**) Hypertrophy-induced expression of miR-208b and pri-miR-208b transcripts in the LV of TAC mice was attenuated by TSA administration; \**P* \< 0.001. (**C**) ChIP for Ezh2 enzyme followed by real-time qPCR for *Anp* and *Bnp* promoters shows reduced binding of Ezh2 in TAC mice; \**P* \< 0.02. (**D**) ChIP for H3K27m3 followed by real-time qPCR for *Anp* and *Bnp* promoters shows reduced H3K27m3 enrichment in TAC mice. (*n* = 4); \**P* \< 0.02. Table 1.Echocardiographic parameters and LV mass in TAC exposed TSA heartsECG parametersShamTAC + vehicleTAC + TSANumber101212Heart rate (beats/min)578 ± 12565 ± 11552 ± 8LVDd (mm)4.1 ± 0.054.5 ± 0.1\*3.9 ± 0.07\*^,†^LVDs (mm)2.7 ± 0.083.6 ± 0.2\*2.6 ± 0.08^†^Fractional shortening (%)34 ± 120 ± 1\*32 ± 1^†^Wall thickness (mm)0.72 ± 0.021.01 ± 0.04\*0.90 ± 0.02\*LV mass (mg)116 ± 4208 ± 13\*147 ± 6\*^,†^[^1]

Expression of *AS β-MHC* is determined by the binding of Ezh2 at the bdP
------------------------------------------------------------------------

We screened the intergenic bdP region of the MHC genes by ChIP-qPCR ([Figure 2](#gkt896-F2){ref-type="fig"}A). We report increased Ezh2 interaction on the intergenic bdP in TAC animals and this was attenuated in TSA-administered mice ([Figure 2](#gkt896-F2){ref-type="fig"}B). This binding pattern was consistent with H3K27m3 enrichment ([Figure 2](#gkt896-F2){ref-type="fig"}C). We determined additional repressive histone marks. We report unremarkable enrichment of H3K9m3 on the bdP in TAC mice ([Supplementary Figure S2](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)). Ezh2 was recently demonstrated to interact with HDAC complexes on suppressed genes ([@gkt896-B24],[@gkt896-B25]). To test the interaction of HDACs on the bdP sequence, LV chromatin was immunopurified from TAC mice using antibodies that recognize HDACs. The intergenic bdP was enriched for HDAC2 binding and not HDAC1 in TAC mice, which was abrogated by TSA ([Figure 2](#gkt896-F2){ref-type="fig"}D). Consistent with the changes in HDAC2 binding to the bdP, reduced binding on *Anp* and *Bnp* promoters in TAC and TSA mice was observed ([Figure 2](#gkt896-F2){ref-type="fig"}E). However, neither Ezh2 nor HDAC2 mRNA expression were altered in these mice ([Supplementary Figure S3](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)). In summary, these results suggest the reduced binding of Ezh2 and HDAC2 correlates with the induction of *Anp* and *Bnp* genes, whereas, the increased binding of these determinants participate in the suppression of *AS β-MHC* and *α-MHC* gene expression in the hypertrophic heart. Figure 2.Pathological hypertrophy induced *α-* to *β-MHC* shift is associated with the interaction of Ezh2 with the intergenic bdP. (**A**) Schematic representation of the cardiac MHC genomic region on chromosome 14 showing primer positions (A--H) used for ChIP walk. (**B**) Enrichment of intergenic bdP sequence was determined by real-time qPCR after Ezh2-ChIP, (**C**) H3K27m3-ChIP and (**D**) HDAC2-ChIP. \**P* \< 0.01; \*\**P* \< 0.03. (**E**) Real-time qPCR for *Anp* and *Bnp* promoters was performed after HDAC2-ChIP. \**P* \< 0.008; \*\**P* \< 0.03. (**F**) Schematic representation of the chromatin binding of *AS β-MHC* transcript and primer positions (3\' and 5\') used in qRT-PCR after RNA-ChIP. (**G**) Chromatin-dependent association of *AS β-MHC* transcript after histone H3 RNA-ChIP. \**P* \< 0.006; \*\**P* \< 0.01. (**H**) Interaction of pri-miR-208b with chromatin by RNA-ChIP using antibodies that recognize histone H3 and Ezh2 in the LV of TAC mice. \**P* \< 0.01. All experiments independently performed *n* = 4.

The *AS β-MHC* transcript associates with chromatin
---------------------------------------------------

Recent evidence suggests that ncRNAs serve to integrate transcriptional responses conferred by chromatin modification ([@gkt896-B26]). Notably, Ezh2 is thought to associate with long ncRNAs to regulate gene expression ([@gkt896-B27],[@gkt896-B28]). To determine whether ncRNA expression in the hypertrophied heart could be directing Ezh2 methyltransferase to the bdP, soluble chromatin from LVs of TAC mice was immunoprecipitated using histone H3 antibody. Specific interaction of the *AS β-MHC* with chromatin was distinguishable from the sense *β-MHC* transcript ([Supplementary Figure S4](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)). The *AS β-MHC* transcript is \>5 kb in length; therefore, we designed primers targeting the 5′- and 3′-ends of the transcript to examine chromatin-dependent association in TAC animals as well as in animals treated with TSA ([Figure 2](#gkt896-F2){ref-type="fig"}F). We detected two regions (end 1 and end 2) at the 3′ sequence of *AS β-MHC* transcript interacting with chromatin and this was reduced in LV chromatin isolated from TAC animals ([Figure 2](#gkt896-F2){ref-type="fig"}G). To extend these studies to the 5′-end, we validated the interaction of the *AS β-MHC* transcript with chromatin isolated from LV tissue. Increased association of the *AS β-MHC* transcript with chromatin in TSA-administered TAC mice was consistent with *β-MHC* expression. These results suggest that the *AS β-MHC* transcript could be interacting with the *β-MHC* gene to regulate histone modifications and gene expression. The *β-MHC* gene contains sense strand specificity, which is thought to also regulate its gene expression, so we examined two ncRNA transcripts that originate from the sense strand, a long pri-miR-208b as well as the short miR-208b. The interaction of the pri-miR-208b with chromatin was determined by RNA-ChIP using histone H3 antibody. TSA administration in TAC mice attenuated pri-miR-208b interaction with chromatin ([Figure 2](#gkt896-F2){ref-type="fig"}H). In contrast, the mature 22-nt miR-208b sequence was undetectable in chromatin isolated from the LV tissue of these animals. Next, we examined whether pri-miR-208b binds to Ezh2 enzyme in the heart. The immunopurification of soluble chromatin using antibody that recognizes Ezh2 shows specific interaction of pri-miR-208b transcript in the hypertrophic heart and this could be attenuated by the HDAC inhibitor, TSA. Taken together, these data suggest several scenarios that could mediate the expression of genes associated with hypertrophy. First, the Ezh2 methyltransferase directly suppresses the expression of target genes including *AS β-MHC* and *α-MHC* in response to hypertrophy. Alternatively, the expression of ncRNAs such as *AS β-MHC* and/or pri-miR-208b transcript could direct Ezh2 interaction to distinct gene promoters such as the intergenic bdP.

Interaction of *AS β-MHC* at the bdP is independent of Ezh2
-----------------------------------------------------------

We explored chromatin-associated RNAs in Sca1+ progenitor cells because the immunoprecipitation procedure requires significant numbers of adult heart cells and the integrity of soluble chromatin was reduced because of collagenase treatments in cardiomyocyte isolation procedures ([@gkt896-B29]). Ezh2 loss-of-function experiments using shRNA (Ezh2KD) were performed in mouse Sca1+ progenitor cells ([Supplementary Figure S5](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)). Ezh2 knockdown efficiency (93%) was determined using qRT-PCR ([Figure 3](#gkt896-F3){ref-type="fig"}A). ChIP results showed significant binding of Ezh2 at the intergenic bdP in non-target cells. We observed reduced *AS β-MHC* and *α-MHC* expression in Ezh2KD cells ([Figure 3](#gkt896-F3){ref-type="fig"}A). In Ezh2KD cells, HDAC inhibition by TSA increased the expression of *AS β-MHC* and *α-MHC* genes and this was consistent with the enrichment of histone H3K9/14ac and H3K4m3 at the intergenic bdP ([Supplementary Figures S6](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1) and [S7](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)). This observation corresponds with Ezh2 binding to the bdP suppressing *AS β-MHC*, whereas the activation of *AS β-MHC* requires H3K9/14ac modification in Ezh2KD cells. Ezh2 knockdown significantly reduced H3K27m3 enrichment at the intergenic bdP ([Figure 3](#gkt896-F3){ref-type="fig"}B). Consistent with our *in vivo* experimental results, we observed increased expression of *Anp* and *Bnp* genes in Ezh2KD cells ([Figure 3](#gkt896-F3){ref-type="fig"}C). ChIP experiments show reduced H3K27m3 on the *Anp* and *Bnp* genes in these cells ([Figure 3](#gkt896-F3){ref-type="fig"}D). Stimulation by TSA increased H3K9/14ac ([Figure 3](#gkt896-F3){ref-type="fig"}E). Taken together, these experimental results suggest Ezh2 confers chromatin silencing events by H3K27m3 to regulate transcriptional responses. Expression of profibrotic genes such as *Tgfb3*, *Spp1* as well as *Sln and Six1* is thought to be regulated by Ezh2 in the adult mouse heart ([@gkt896-B12]). We report in Ezh2KD cells, *Tgfb3* was upregulated, whereas *Spp1* and *Six1* genes were suppressed. In TAC animals, the expression of *Tgfb3*, *Spp1* and *Sln* was increased while TSA administration attenuated gene expression ([Figure 3](#gkt896-F3){ref-type="fig"}F). These results in the mouse are consistent with *in vitro* observations and suggest Ezh2 could play a role in regulating H3K27m3-mediated gene expression in the hypertrophied heart. We hypothesized that Ezh2 binding confers the expression of hypertrophic as well as profibrotic genes through interaction with ncRNAs, such as *AS β-MHC* and pri-miR-208b. To test this, we examined the interaction of both transcripts associated with immunoprecipitated soluble chromatin prepared from Ezh2-deficient cells. The specific interaction of *AS β-MHC* transcript at the 3′-end remained unchanged on chromatin ([Figure 3](#gkt896-F3){ref-type="fig"}G). Interestingly, TSA increased *AS β-MHC* expression as well as its interaction with chromatin which was correlated with reduced *β-MHC* gene expression. We observed a strong reduction of interacting pri-miR-208b transcript on chromatin, which was not changed by TSA treatment. These results suggest that the interaction of *AS β-MHC* transcript with chromatin inversely correlates with *β-MHC* gene expression in TAC+TSA animals. In addition, experiments in Ezh2KD cells also indicate the interaction of pri-miR-208b transcript with chromatin was dependent on Ezh2 enzyme. In conclusion, the *AS β-MHC* interaction with chromatin was associated with *β-MHC* gene expression in mice and this was regulated by Ezh2 binding at the intergenic bdP in pathological hypertrophy. Figure 3.Chromatin association of *AS β-MHC* transcript is independent of Ezh2 and regulates *β-MHC* gene expression. (**A**) Gene expression was assessed by qRT-PCR in non-target (nt), Ezh2-deficient (Ezh2KD) and Ezh2KD cells stimulated with TSA. \**P* \< 0.001; \*\**P* \< 0.01. (**B**) H3K27m3-ChIP for intergenic bdP in Ezh2KD cells. \**P* \< 0.001; \*\**P* \< 0.01. (**C**) qRT-PCR detection of mRNA for Ezh2-regulated genes. \**P* \< 0.001; \*\**P* \< 0.015. (**D**) H3K27m3-ChIP for *Anp* and *Bnp* promoters in non-target (nt), Ezh2-deficient (Ezh2KD) and Ezh2KD cells stimulated with TSA; \**P* \< 0.015. (**E**) H3K9/14ac-ChIP for *Anp* and *Bnp* promoters in non-target (nt), Ezh2-deficient (Ezh2KD) and Ezh2KD cells stimulated with TSA; \**P* \< 0.005. (**F**) mRNA expression for Ezh2 cardiac gene targets determined by qRT-PCR in mice LV. \**P* \< 0.005. (**G**) Loss of Ezh2 reduces the binding of pri-miR-208b but not *AS β-MHC* on chromatin binding of pri-miR-208b, whereas the binding of *AS β-MHC* transcript remained unaffected. \**P* \< 0.01. All experiments independently performed *n* = 5.

Because *AS β-MHC* transcript binding to chromatin is reduced in the hypertrophic heart, we hypothesized that knockdown of *AS β-MHC* (*AS β-MHC* KD) could regulate the binding of Ezh2 at key cardiac genes. To do this, we used shRNA-mediated knockdown strategy to achieve efficient reduction of the *AS β-MHC* (86%) transcript. Knockdown of *AS β-MHC* did not alter Ezh2 binding nor its determinant H3K27m3 on the intergenic bdP as determined by ChIP-qPCR ([Supplementary Figures S8](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1) and [S9](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)). These results indicate that Ezh2 binding to intergenic bdP as well as to *Anp* and *Bnp* genes occurs independently of *AS β-MHC* transcript. Compatible with our hypothesis that *AS β-MHC* transcript is not guiding the interaction of Ezh2 with chromatin, we show reduced association of the *AS β-MHC* transcript with chromatin in *AS β-MHC* KD cells ([Supplementary Figure S10](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)). Interestingly, the interaction of the pri-miR-208b transcript with chromatin remained unaltered in *AS β-MHC* KD cells, whereas TSA exposure reduced this association. These data suggest that the *AS β-MHC* transcript does not guide Ezh2 to the bdP of the *MHC* gene.

Interaction of Ezh2 with chromatin is determined by pri-miR-208b
----------------------------------------------------------------

Next, we examined whether pri-miR-208b could direct Ezh2-mediated H3K27m3 modification on key cardiac genes. Primary miR transcripts are processed to mature miRNAs processed to mature miRNAs (∼22 nt in length) by RNase III family enzymes such as Drosha and Dicer ([@gkt896-B30]). Using shRNA construct, we targeted the knockdown of the pri-miR-208b and miR-208b transcripts (90% reduction) in 208b-KD cells ([Figure 4](#gkt896-F4){ref-type="fig"}A). We used RNA-ChIP to determine the association of pri-miR-208b transcript with chromatin and show significant reduction in 208b-KD cells ([Figure 4](#gkt896-F4){ref-type="fig"}B). We then examined gene expression by qRT-PCR. While miR-208b deletion in mice show no changes in MHC gene expression ([@gkt896-B10]), the loss of pri-miR-208b in 208b-KD cells increased the expression of bdP (*AS β-MHC* and *α-MHC* genes) and downregulated *β-MHC* ([Figure 4](#gkt896-F4){ref-type="fig"}A). We examined whether the chromatin interaction of *AS β-MHC* transcript resulted in *β-MHC* suppression in these cells. Association of the *AS β-MHC* transcript with chromatin was increased and inversely correlated with *β-MHC* gene expression in 208b-KD cells ([Figure 4](#gkt896-F4){ref-type="fig"}B). These changes to MHC gene expression suggest that the chromatin interaction of pri-miR-208b may be critical for epigenetic regulation of the intergenic bdP. Next, we assessed whether the loss of pri-miR-208b transcript altered Ezh2 and H3K27m3 association with the intergenic bdP region. ChIP results confirmed reduced Ezh2 binding at the bdP ([Figure 4](#gkt896-F4){ref-type="fig"}C) and this was consistent with reduced H3K27m3 modification in 208b-KD cells ([Figure 4](#gkt896-F4){ref-type="fig"}D). This was associated with H3K27m3 marks in these cells ([Figure 4](#gkt896-F4){ref-type="fig"}D). Release of Ezh2 from the intergenic region was consistent with H3K9/14ac increase in TSA-stimulated cells and increased *AS β-MHC* and *α-MHC* gene expression ([Figure 4](#gkt896-F4){ref-type="fig"}E). These results suggest the interaction of Ezh2 with the intergenic bdP requires pri-miR-208b transcript for gene silencing. We then determined whether the loss of pri-miR-208b transcript could deregulate other Ezh2 gene targets, and show increased *Anp* and *Bnp* gene expression ([Figure 5](#gkt896-F5){ref-type="fig"}A). Furthermore, additional Ezh2-regulated genes including the expression of *Tgfb3* and *Spp1* genes were increased, whereas *Six1* and *Sln* remained unchanged in 208b-KD cells. Taken together, these experimental results support the idea that the pri-miR-208b transcript regulates gene expression by its interaction with Ezh2 and chromatin. Consistent with this idea, binding of Ezh2 and its determinant, H3K27m3, was reduced on the *Anp* and *Bnp* promoters in 208b-KD cells ([Figure 5](#gkt896-F5){ref-type="fig"}B and C). Therefore, the loss of pri-miR-208b results in changes to expression of Ezh2-regulated genes such as *Anp, Bnp, Tgfb3, Spp1* as well as *AS β-MHC* and *α-MHC* genes. We examined whether pri-miR-208b-dependent chromatin binding of Ezh2 could regulate the expression of cardiac stem cell markers in TAC animals because an essential role for Ezh2 in adult muscle and neuronal regeneration after injury has been recently documented ([@gkt896-B31],[@gkt896-B32]). Increased expression of endogenous cardiac stem cell (eCSC) genes such as *Oct4* and *Sox2* was observed, whereas *Nanog* was downregulated in 208b-KD cells ([Figure 5](#gkt896-F5){ref-type="fig"}D). TSA administration downregulated the expression of *Oct4* and *Sox2* while derepressing *Nanog* expression in 208b-KD cells. We extended these observations in LVs of TAC mice and report increased *Oct4, Sox2* and decreased *Nanog* expression consistent with our *in vitro* observations ([Figure 5](#gkt896-F5){ref-type="fig"}E). Release of Ezh2 from gene targets in TAC animals as well as the activation of Ezh2-regulated genes in 208b-KD cells suggests that the pri-miR-208b transcript could regulate the chromatin binding of the Ezh2 enzyme. The precise role of pri-miR-208b in regulating eCSC marker expression remains to be investigated. Figure 4.Loss of pri-miR-208b transcript reduces the interaction of Ezh2 binding at the intergenic bdP. (**A**) qRT-PCR for RNA levels in 208b-KD cells shows activation of *AS β-MHC* and *α-MHC* genes. \**P* \< 0.01; \*\**P* \< 0.02. (**B**) RNA-ChIP in 208b-KD cells shows increased chromatin binding for *AS β-MHC* transcript. \**P* \< 0.01; \*\**P* \< 0.02. (**C**) Ezh2-ChIP in 208b-KD cells was assessed for intergenic bdP. \**P* \< 0.001; \*\**P* \< 0.004. (**D**) H3K27m3-ChIP showing reduced enrichment for bdP sequence. \**P* \< 0.01; \*\**P* \< 0.02. (**E**) H3K9/14ac-ChIP for intergenic bdP in 208b-KD cells. \**P* \< 0.001; \*\**P* \< 0.01. All experiments independently performed *n* = 5. Figure 5.Loss of pri-miR-208b is associated with the expression of Ezh2 gene targets. (**A**) Relative mRNA expression of Ezh2 gene targets was assessed by qRT-PCR in 208b-KD cells. \**P* \< 0.003; \*\**P* \< 0.015. (**B**) Ezh2 binding to *Anp* and *Bnp* promoters was reduced in 208b-KD cells; \**P* \< 0.002. (**C**) H3K27m3-ChIP in 208b-KD cells followed by real-time qPCR detection of *Anp* and *Bnp* promoters; \**P* \< 0.01. (**D**) Loss of pri-miR-208b is associated with the expression of stem cell genes. \**P* \< 0.007. (**E**) mRNA expression for eCSC markers in Sham, TAC and TAC+TSA mice. \**P* \< 0.001; \*\**P* \< 0.01. All experiments independently performed *n* = 5.

Regulation by pri-miR-208b transcript
-------------------------------------

Our results suggest a regulatory function for the pri-miR-208b at the transcriptional level mediated by the PcG protein, Ezh2 as well as post-transcriptional regulation in the hypertrophied heart. To further characterize the functions of *pri-miR-208b*, we studied gene expression changes in 208b-KD cells because mature miRNAs suppress mRNA expression by binding to 3′-UTR sequences ([@gkt896-B30]). Because miR-208b is a repressive determinant of *Med13* (*THRAP1*) genes ([@gkt896-B9],[@gkt896-B10]), we examined gene expression in 208b-KD cells. [Figure 6](#gkt896-F6){ref-type="fig"}A shows elevated *Med13* expression in 208b-KD cells suggesting regulation is dependent on mature miR-208b. We also assessed the expression of exonic and intronic *Med13* gene sequences. The expression of intronic *Med13* does not change in 208b-KD cells ([Figure 6](#gkt896-F6){ref-type="fig"}B). These data suggest that miR-208b silences *Med13* expression post-transcriptionally. In contrast, we observed elevated expression of intronic and exonic sequences of the *α-MHC* gene in 208b-KD cells ([Figure 6](#gkt896-F6){ref-type="fig"}B) suggesting that pri-miR-208b transcriptionally regulates gene expression. These data are also consistent with reduced Ezh2 interaction at the bdP in 208b-KD cells ([Figure 4](#gkt896-F4){ref-type="fig"}C). The expression of Ezh2 remains unchanged in 208b-KD cells ([Figure 4](#gkt896-F4){ref-type="fig"}A). To determine whether gene targets of pri-miR-208b are regulated transcriptionally, we isolated nuclear and cytosolic RNAs ([@gkt896-B21]). We observe predominant expression of miR-208b in cytosolic fractions of Sca1+ cells, whereas the pri-miR-208b transcript was detected in both the nuclear and cytosolic preparations ([Figure 6](#gkt896-F6){ref-type="fig"}C). As expected, the expression of snoRNA was enriched in the nuclear compartment ([Supplementary Figure S11](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)), whereas the expression of 18s rRNA was cytosolic ([Supplementary Figure S12](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)). As controls for the nuclear and cytosolic fractions, we show by protein immunoblotting the isolation of Brm and GAPDH, respectively ([Supplementary Figure S13](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)). Taken together, these results suggest the mature miR-208b transcript is less likely to regulate gene silencing in the nucleus. We then examined whether pri-miR-208b transcript could directly interact with the intergenic bdP sequence. First, *in silico* analysis indicates specific 5′-end complementarity between the pri-miR-208b transcript and the intergenic bdP at sequences --1227 to --1330 relative to the α-MHC transcription start site ([Figure 6](#gkt896-F6){ref-type="fig"}D). Second, we designed a synthetic RNA oligomer using the pri-miR-208b sequence to determine its binding efficiency to the bdP using *in vitro* dsDNA/RNA immunoprecipitation assay. This procedure involves hybridization of biotin-incorporated RNA oligonucleotides with DNA, which are immunoprecipitated with streptavidin beads ([@gkt896-B33]). Following immunoprecipitation, the isolates are treated with ribonucleases, RNase H or RNase V1. The endonuclease RNase H specifically catalyzes the cleavage of RNA in RNA/DNA hybrids, whereas the RNase V1 enzyme does not distinguish base-paired RNA/DNA hybrids. To quantify enrichment of the bdP, we used qPCR. Immunoprecipitation indicates the pri-miR-208b sequence interacts specifically with the bdP, which was confirmed by RNase H cleavage, as shown in [Figure 6](#gkt896-F6){ref-type="fig"}E. Similarly, treatment with the RNase V1 ribonuclease abolished bdP enrichment. Taken together, these results suggest the pri-miR-208b transcript interacts with the bdP template. Figure 6.Regulation by the pri-miR-208b transcript. (**A**) Increased expression of *Med13* gene in 208b-KD cells; \**P* \< 0.0038 (**B**) qRT-PCR of exonic and intronic sequences shows transcriptional activation of *α-MHC* gene in 208b-KD cells; \**P* \< 0.0005 (**C**) Wild-type Sca1+ cells were assessed for miR expression in cytosolic and nuclear fractions. \**P* \< 0.0007. (**D**) Pri-miR-208b recognition sequence within the bdP. (**E**) *In vitro* dsDNA/RNA binding assay using biotin-tagged RNA oligomers followed by real-time qPCR of the bdP sequence. Fold enrichment was calculated relative to non-specific oligonucleotide binding. \**P* \< 0.0038. All experiments independently performed *n* = 4.

These results show for the first time that the association of the pri-miR-208b transcript with Ezh2 enzyme is linked to changes in gene function in the hypertrophied LV. This concept is supported by the observation that loss of pri-miR-208b transcript is associated with altered chromatin binding of Ezh2 and derepression of Ezh2-regulated genes. However, the chromatin interaction of *AS β-MHC* occurs independent of pri-miR-208b and Ezh2 enzyme. To date, there is little information regarding the chromatin interaction of primary miRNAs regulating epigenetic states and gene expression. Besides functioning as precursor transcripts for miR processing, the current data support novel chromatin regulatory roles for primary miR transcripts in the hypertrophied heart.

While our laboratory is intensely refining the techniques to isolate heart-derived cardiomyocytes for the specific purpose to study chromatin-associated RNAs from small cell numbers, many of the current observations published use considerably larger numbers of cultured cells ([@gkt896-B34],[@gkt896-B35]). To explore the mechanism of gene regulation, we studied the mouse neonatal ventricular cardiomyocytes to show that gene expression changes were consistent with our observations with Sca1+ cells. For example, we observed the upregulation of *α-MHC* and *AS β-MHC* in TSA-stimulated cells as well as the downregulation of *Anp* genes ([Supplementary Figure S14](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt896/-/DC1)). TSA stimulation did not change the expression of *pri-miR-208a* and *pri-miR-208b* transcripts. While our studies highlight similarities between terminally differentiated muscle and Sca1+ progenitor cells, we cannot rule out other regulatory differences mediating chromatin-associated ncRNAs.

DISCUSSION
==========

The PcG protein, Ezh2, is a key regulatory enzyme required for tissue-specific gene silencing. We observed binding of Ezh2 to the *Anp* and *Bnp* genes in LV tissues isolated from adult hearts. Pressure overload by TAC surgery results in the activation of fetal genes such as *Anp* and *Bnp* consistent with reduced binding of Ezh2 on these genes. Conversely, the repression of adult genes such as *α-MHC* and *AS β-MHC* in TAC animals is associated with increased Ezh2 binding and H3K27m3 modification at the bdP ([Figure 7](#gkt896-F7){ref-type="fig"}). Although HDAC inhibition by TSA is known to attenuate the induction of fetal genes and repression of adult-specific genes such as *α-MHC*, the precise molecular regulators targeted by TSA still remain poorly understood. We show that derepression of *α-MHC* and *AS β-MHC* genes by TSA is associated with the release of Ezh2 and H3K27m3 modification at MHC genes. The chromatin binding of Ezh2 in the adult heart is essential for maintaining the homeostatic gene expression. Figure 7.Schematic representation of the α/β MHC gene regulating events at the intergenic bdP mediated by ncRNA. Cardiac hypertrophy is associated with H3K27m3 of intergenic bdP by the PcG methyltransferase protein, Ezh2 and suppression of coding *α-MHC* and non-coding *AS β-MHC* gene expression. Increased expression of pri-miR-208b is associated with Ezh2 interaction at the bdP in cardiac hypertrophy. HDAC inhibition by TSA attenuates cardiac hypertrophy by restoring the expression of *α-MHC* and *AS β-MHC* genes and this is associated with hyperacetylation of the intergenic bdP as well as the release of Ezh2/pri-miR-208b complex. Restoration of *AS β-MHC* expression results in chromatin binding and inhibition of sense *β-MHC* transcription.

As shown in [Figure 7](#gkt896-F7){ref-type="fig"}, MHC chromatin content as well as specific co-regulatory complexes serve to integrate ncRNAs to distinct transcriptional responses in the hypertrophied heart. We propose that the pri-miR-208b transcript as a substrate for histone modification ([@gkt896-B36]). We observed the pri-miR-208b transcript mediates the *α-* to *β-MHC* switch in the hypertrophied heart. HDAC inhibition by TSA attenuates pri-miR-208b dependent-chromatin binding in TAC animals. In the hypertrophied heart, recruitment of Ezh2 is mediated by pri-miR-208b chromatin interaction. *In vitro* silencing of either the pri-miR-208b transcript or Ezh2 enzyme are associated with gene expression changes that were comparable with pri-miR-208b and Ezh2 knockdown. Specifically, the reduced chromatin interaction of pri-miR-208b transcript in miR-208b-KD cells alters Ezh2 binding to target genes. This was associated with the derepression of Ezh2-regulated genes in pri-miR-208b knockdown cells. The loss of *AS β-MHC* transcript in cardiac progenitors did not change the expression of Ezh2-regulated genes. This suggests that pri-miR-208b could regulate the binding of Ezh2 and H3K27m3 at genes. Experimental results derived from TAC animals suggest increased chromatin interaction of pri-miR-208b transcript could mediate the release of Ezh2 from *Anp* and *Bnp* genes, while increase Ezh2 binding to the bdP in the hypertrophied heart.

Recent evidence suggests that antisense transcription is critical for H3K27m3-mediated silencing ([@gkt896-B37]). The long ncRNA, *HOTAIR*, interacts with Ezh2 ([@gkt896-B34],[@gkt896-B35],[@gkt896-B38]). While, a mouse ortholog to the *HOTAIR* transcript (*mHOTAIR*) has been reported, its the function in the heart remains uncharacterized ([@gkt896-B39]). We report no appreciable expression of the *HOTAIR* transcript in our experiments. The molecular basis of ncRNA-dependent chromatin interactions conferring gene-regulating epigenetic changes in the heart remains incomplete ([@gkt896-B40],[@gkt896-B41]). The experimental results presented in this study suggest that ncRNA could guide chromatin-modifying complexes to regulate hypertrophy-associated gene expression ([@gkt896-B42]). Recent studies also indicate that TSA attenuates pathological hypertrophy in mice as well as regulates the co-repressive Brg1-HDAC complexes interacting with the bdP of the intergenic region ([@gkt896-B6]). The mechanism underlying the induction of stem cell population within the myocardium in response to increased pressure overload is poorly understood; however, it is thought to contribute negatively to ventricular function in the pathological heart ([@gkt896-B43]). Our results also suggest a novel role for HDAC inhibition in regulating cardiac stem cell genes by mechanisms that involve ncRNA--chromatin interaction. Not only is this work of direct therapeutic relevance to hypertrophy, but will also be important for our understanding of new mechanisms of gene regulation conferred by interacting ncRNAs that influence chromatin structure and function.
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[^1]: TAC, transverse aortic constriction; LVDd and LVDs, left ventricular diameter at diastole or systole; \**P* \< 0.01 versus Sham group; ^†^*P* \< 0.05 versus TAC + vehicle group.
